261149
Lutetium
ingot, 99.9% trace rare earth metals basis
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
Lu
CAS Number:
Molecular Weight:
174.97
EC Number:
MDL number:
UNSPSC Code:
12352300
PubChem Substance ID:
Recommended Products
Quality Level
assay
99.9% trace rare earth metals basis
form
ingot
reaction suitability
reagent type: catalyst
core: lutetium
resistivity
54 μΩ-cm, 20°C
bp
3402 °C (lit.)
mp
1663 °C (lit.)
density
9.84 g/mL at 25 °C (lit.)
SMILES string
[Lu]
InChI
1S/Lu
InChI key
OHSVLFRHMCKCQY-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xuejuan Wang et al.
European journal of nuclear medicine and molecular imaging, 39(12), 1876-1885 (2012-08-29)
Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled peptides is of interest for tumour localization, staging, therapy follow-up and targeted radionuclide therapy. The peptides used clinically are exclusively agonists, but recently we have shown that the radiolabelled somatostatin-based
S Shcherbinin et al.
Physics in medicine and biology, 57(18), 5733-5747 (2012-09-06)
We investigated the quantitative accuracy of SPECT/CT imaging studies as would be performed before and after targeted radionuclide therapy (TRT) using phantom experiments with (i) (99m)Tc, (ii) ¹⁷⁷Lu and (iii) ⁹⁰Y/¹⁷⁷Lu. While the experiment with (99m)Tc imitated a diagnostic scan
Rebecca A Dumont et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 762-769 (2013-03-16)
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer and is an attractive target for radionuclide therapy. In addition, inhibition of the protein kinase mammalian target of rapamycin (mTOR) has been shown to sensitize various cancer cells to the
Arnaud Dieudonné et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(2), 236-243 (2012-12-20)
Dose kernel convolution (DK) methods have been proposed to speed up absorbed dose calculations in molecular radionuclide therapy. Our aim was to evaluate the impact of tissue density heterogeneities (TDH) on dosimetry when using a DK method and to propose
S M van den Bosch et al.
Nuclear medicine and biology, 40(3), 415-423 (2013-02-06)
We report on our evaluation of the strain-promoted cyclooctyne-azide cycloaddition reaction for use in tumor pretargeting, comprising a side-by-side comparison of probes 1-3 bearing three distinct cyclooctyne moieties based respectively on the 1st and 2nd generation difluorinated cyclooctyne and the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
